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Abstract 
Various trials of ovarian cancer screening programs have been reported worldwide. In 2011, one 
of the most famous papers indicated that annual screening using CA125/transvaginal sonography 
(TVS) did not reduce ovarian cancer mortality in the United States of America (USA). To 
investigate the validity of ovarian cancer screening, we verified the analyses of previous reports. At 
first, we obtained the USA datasets that were used for the analyses and identified many patients in 
whom cancers were accidentally detected several years after the screening period. We thus 
performed a new prognostic comparison between the screening group (cancers that were 
detected through screening or within one year after screening) and the control group (cancers 
that were found more than one year after screening, without screening, or in the original control 
group). The results showed that the prognoses of the screening group were significantly better 
than those of the control group (p=0.0017). In addition, the screening group contained significantly 
fewer stage IV cases than the control group (p=0.005). In another screening in the United 
Kingdom, ovarian cancer was detected at a relatively earlier stage (stage I/II: 44%), while the rate of 
stage IV detection was low (4%). Very recently, this team showed significant difference in the rates 
with and without screening (p=0.021) when prevalent cases were excluded and indicated the 
delayed effect of screening. These results contrasted with the USA data. In other studies in the 
USA and Japan, annual screening was also associated with a decreased stage at detection. New 
histopathological, molecular and genetic studies have recently provided two categories of ovarian 
carcinogenesis. Type I carcinomas are slow-growing neoplasms that often develop from benign 
ovarian cysts. Type II carcinomas are high-grade clinically aggressive neoplasms. The rate of type II 
carcinomas is significantly higher in Europe and the USA than in Asia (p<0.001). Conversely, type 
I carcinomas are relatively common in Asia. These data theoretically imply that annual screening 
would be more effective in Asia. 
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Introduction 
Various trials of ovarian cancer screening 
programs have been reported worldwide. One of 
these reports was an examination of a screening 
program for prostate, lung, colorectal and ovarian 
cancer (PLCO) in the United States of America (USA) 
that was performed using a randomized controlled 
trial [1, 2] and the largest study for ovarian cancer 
screening with survival data. The screening strategy 
involved annual screening with transvaginal 
sonography (TVS) and CA125 level measurements 
(CA125 cut-off of ≧35. Both methods were performed 
for three years. CA125 levels were measured at years 
four and five. After that, follow-up was performed for 
more than five years). The authors’ conclusion was 
that simultaneous screening with measurement of the 
CA 125 level and TVS did not reduce ovarian cancer 
mortality compared with the standard care.  
To investigate the validity of ovarian cancer 
screening, we verified the analyses of previous 
reports. For our analysis, we selected reports 
throughout the world in which large-scale 








than 30,000. We herein discuss whether ovarian 
cancer screening is globally effective. 
Original analysis of the PLCO screening 
data 
The PLCO screening arm involved a randomized 
controlled trial (RCT) of 78,216 females aged 55 to 74 
years assigned to receive either annual screening 
(n=39,105) or usual care (n=39,111) at 10 centers across 
the USA between 1993 and 2001 (white, non-Hispanic: 
67,401 (86.2%), Asian: 2,567 (3.3%)). Ovarian cancer 
was diagnosed in 212 patients (0.54%) in the 
intervention group and 176 patients (0.45%) in the 
usual care group. The stage distribution in the 
intervention group was as follows: 32 (15%) cases of 
stage I disease, 15 (7%) cases of stage II disease, 120 
(57%) cases of stage III disease and 43 (20%) cases of 
stage IV disease, indicating that the majority of 
patients had cancer at stage III or above. The 
distribution of cancer histologies included 116 (80%) 
cases of serous lesions, five (3%) cases of mucinous 
lesions, 19 (13%) cases of endometrioid lesions and six 
(4%) cases of clear cell lesions, thus indicating that the 
majority of cases involved serous cancer. We 
identified a large number of patients whose cancers 
were accidentally detected several years after the 
screening period in the intervention group. 
 We obtained the authors’ datasets and 
performed a new analysis to examine the efficacy of 
annual screening. We divided the patients who were 
currently diagnosed with ovarian cancer into two 
groups to investigate the direct effect of screening. 
Group A (101 patients) included patients whose 
ovarian cancers were detected through annual 
screening (CA125 and/or TVS) or within one year 
after screening. Group B (344 patients) included 
patients in the screening group whose ovarian cancers 
were found over one year after screening due to the 
patient experiencing symptom, and patients in the no 
screening or in the control group. We drew 
Kaplan-Meier survival curves for Group A and Group 
B. The results showed a significantly better prognosis 
for patients in Group A than those in Group B 
(median survival; 6.1 vs. 3.3 years, p=0.0017 using the 
log-rank test) (Figure 1). Statistical analyses were 
performed by two evaluators using the JMP PRO11 
software program (SAS Institute Inc). In addition, the 
former group contained significantly fewer stage IV 
cases than the latter group (13% vs. 29%, respectively, 
p=0.005). Moreover the rate of surgery resulting in no 
macroscopically residual disease was relatively 
higher in the former group than in the latter group 
(50,0% vs.38.0%, respectively, p=0.034). In brief, if a 
patient receives an annual screening examination for 
ovarian cancer, the stage at detection of advanced 
cases may shift from stage IV to stage III or below, 
thus allowing the patients monitored with annual 
screening to undergo more thorough surgeries than 
those without screening. Therefore, the patients 
whose ovarian cancers are found during the annual 
screening or within one year after the screening may 





Figure 1. Kaplan-Meier survival curves for Group A (102 patients whose 
ovarian cancers were detected through annual screening or within one year 
after screening) and Group B (344 patients whose ovarian cancers were found 
symptomatically over one year after screening, in the no screening or in the 
control group). The results showed a significantly better prognosis in Group A 
than in Group B (p=0.0017). Hazard Ratio: 0.6235, 95% 0.4517 -0.8794. 
 
However, we could not definitively determine 
the efficacy of screening because the survival rates 
must be compared after randomization with or 
without screening in order to avoid a “lead time bias” 
which is caused by the length of time between the 
detection of a cancer by screening and its usual 
clinical presentation after the patient’s symptoms. 
Our original study of the PLCO screening data was a 
retrospective analysis, and was limited by lead time 
bias, which means that its results must therefore be 
interpreted with caution. However, the PLCO study 
was unable to find positive results even in the stage 
shift and the ratio of complete surgery probably 
because their methods have various weak points with 
respect to screening, such as 1) the group undergoing 
annual screening included women who did not 
receive screening; and 2) many patients with ovarian 
cancer in the screening group were diagnosed more 
than one year after screening. Accordingly, there were 
many ovarian cancer cases that were thought to have 
occurred several years after the screening period in 
the intervention group, which were not related to the 
direct effect of screening. As mentioned above, doubt 
has been raised as to whether the content of the 
screening intervention was sufficient.  




 The United Kingdom Collaborative Trial 
of Ovarian Cancer Screening 
Currently, the largest screening trial is ongoing. 
The United Kingdom Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS) is an RCT of 202,638 
women aged 50-74 years (control: 101,359, 
multimodal screening (MMS): 50,640, TVS alone: 
50,639, white 96.5%, Asian 0.9%) who were assigned 
between 2001 and 2005 [3-5]. The MMS protocol 
included annual CA125 screening interpreted using a 
patented “Risk of Ovarian Cancer” algorithm (ROCA) 
with TVS as a second-line test [6, 7]. Ovarian cancer 
was diagnosed in 38 (0.08%) patients in the MMS 
group and 32 (0.06%) patients in the TVS group, 
including screen negative cases. The distribution of 
the cancer histologies was similar to that of the PLCO 
group. The distribution of the cancer stages in the 
MMS group was as follows: 17 (45%) patients with 
stage I disease, two (5%) patients with stage II disease, 
19 (50%) patients with stage III disease and zero (0%) 
patients with stage IV disease. The distribution of the 
cancer stages in the TVS group was as follows: 10 
(31%) patients with stage I disease, two (6%) patients 
with stage II disease, 10 (53%) patients with stage III 
disease and two (9%) patients with stage IV disease. 
In total, the stages at detection were relatively earlier 
(stage I/II: 44%), and the rate of stage IV disease was 
very small (4%). For women at high risk of ovarian 
cancer, the same UK team previously demonstrated a 
stage shift in the patients who underwent screening 
within one year compared with the patients who were 
diagnosed more than one year after the last negative 
screening (≥ Stage IIIc; 26.1% vs 85.7%, respectively, 
p=0.009) [8]. Very recently, the UK team reported the 
final mortality rate after extending the screening to 
December 2011 [9]. Follow-up was extended to 
December 2014. A prespecified analysis of death from 
ovarian cancer in an MMS cohort versus no screening 
with the exclusion of prevalent cases showed a 
significantly different death rate (p=0.021), with an 
overall average mortality reduction of 20% (a 
reduction of 8% in years 0-7 and 28% in years 7-14) in 
favor of MMS. They insisted that this late effect of 
screening was predictable in view of the unavoidable 
interval from randomization to diagnosis and then 
death. For example, the median interval from 
randomization to death in the no screening cohort 
was more than 8 years. The UK team suggested that 
MMS screening was more effective after 7 years of 
screening. Thus, the results differed from those of the 
PLCO screening due to the extension of the screening 
and follow-up periods. 
The Kentucky Screening Study 
In the Kentucky Screening Study, single-arm 
annual TVS screenings of 37,293 women were 
performed from 1987 to 2011 [10,11], through which 
47 cases of ovarian cancer were detected. 
Additionally, 12 cases were diagnosed as ovarian 
cancer within 1 year of a negative screening. We 
obtained clinical data from the author by personal 
communication. The stage distribution of the 59 cases 
in the annual screening group was as follows: 23 
(39%) stage I lesions, 13 (22%) stage II lesions, 23 
(39%) stage III lesions, and zero (0%) stage IV lesions, 
with a 61% rate of early stage (I/II) disease. The 
distribution of cancer histologies included 38% with 
serous lesions, 2% with a mucinous lesion, 26% cases 
with endometrioid lesions, 4% cases with clear cell 
lesions and 30% cases with other adenocarcinomas. 
The survival rate of the patients with ovarian cancer 
in the annual screening group was 74.8% ± 6.6% at 
five years, which compared favorably with the five 
year survival rate of 53.7% ± 2.3% among the patients 
with ovarian cancer who did not undergo screening 
(p<0.001). The study algorithm indicated that patients 
began receiving screenings at four- to six- week 
intervals if there were any abnormal adnexal findings, 
such as a benign tumor. The authors concluded that 
annual TVS screening is associated with a decreased 
stage at detection, as well as a decrease in case-specific 
ovarian cancer mortality. Furthermore, the rate of 
stage IV disease was zero. However, that study was 
not an RCT and demonstrated a significant 
healthy-volunteer effect, which makes it difficult to 
accurately interpret the outcomes [12]. Moreover, 
compared with the PLCO data, the rate of serous 
cancers was relatively low and the rate of 
endometrioid cancers was relatively high.  
The Japanese study 
In Japan, the results of the Shizuoka Cohort 
Study of Ovarian Cancer Screening were recently 
reported. This study was an RCT of 82,487 low-risk 
postmenopausal women (intervention group: 41,688, 
control group: 40,799) who were screened using 
annual TVS and CA125 levels based on a cut-off value 
[13]. Women with scan findings of benign diseases 
returned for repeat scans every 3–6 months. The total 
number of ovarian cancers in the intervention group 
was 27 (0.06%). The stage distribution in the 
intervention group was as follows: 17 (63%) cases of 
stage I disease, one (4%) case of stage II disease, seven 
(26%) cases of stage III disease and two (7%) cases of 
stage IV disease. The distribution of the cancer 
histologies included eight (30%) cases of serous 
lesions, four (15%) cases of mucinous lesions, five 




(19%) cases of endometrioid lesions, nine (33%) cases 
of clear cell lesions and one (4%) case of another 
cancer, meaning that the majority of the cases 
involved histologies other than serous cancer. The 
proportion of stage I/II ovarian cancers was higher in 
the screened group (67%) than in the control group 
(44%), but this difference did not reach statistical 
significance (p=0.116). The rate of complete surgical 
excision was higher in the screening group (21; 78%) 
than in the control group (15; 47%) (p=0.018). The 
mortality rates in that study are unknown. 
 Two types of ovarian cancer 
New histopathological, molecular and genetic 
studies have recently provided a better model for 
ovarian carcinogenesis, including two broad 
categories, designated as type I, in which precursor 
lesions in the ovaries have clearly been described, and 
type II, in which such lesions have not been clearly 
described and tumors may develop de novo from the 
tubal and/or ovarian surface epithelium [14]. Type I 
carcinomas are, in general, slow-growing, indolent 
neoplasms, and include low-grade serous (rare 
tumors), mucinous, endometrioid, clear cell and 
transitional cell cancers. As we previously reported, 
Type I carcinomas often develop from benign ovarian 
cysts, and those detected within one year (mean: 7.1 ± 
2.8 months) after the visit for follow-up of ovarian 
cysts were mostly stage I diseases (17/19; 89%) [15]. In 
contrast, type II carcinomas are high-grade clinically 
aggressive neoplasms, and include a majority of 
high-grade serous cancers, which are often found at 
an advanced stage and are highly genetically 
unstable. The majority of type II carcinomas, but not 
type II carcinomas, have TP53 mutations, and almost 
half of the cases involve hypermethylation, or a 
dysfunction of the breast cancer gene (BRCA 1/2). 
These biological aspects are evidence of the aggressive 
nature of type II carcinoma. 
Different effects of ovarian cancer 
screening among different races 
Among different races (Europeans, Asians and 
subjects in the USA), there are significant differences 
in the rates of the different histological subtypes of 
ovarian cancer [16-21]. Figure 2 shows the rates of 
these histological subtypes of ovarian cancer in 
Europe, the USA and Asia. The rate of aggressive 
ovarian cancer, such as high-grade serous cancer 
(type II), is significantly higher in Europe and the 
USA than in Asia (Figure 3, p<0.001). Conversely, 
type I carcinomas, indolent carcinomas arising from 
precursors, are relatively common in Asia. These data 
theoretically imply that ovarian cancer screening 
using CA125/TVS would be more effective in Asia, 
detecting cancer at an earlier stage or its precursor 
such as ovarian cyst and thus reducing mortality. In 
addition, annual screening can be used to detect 
precursors of type I ovarian cancer, such as cystic 
tumors, so patients can be closely observed.  
 
 
Figure 2. Comparison of the rates of different histological subtypes of ovarian cancer in Europe, the USA and Asia.  





Figure 3. Comparison of the rates of type I and type II ovarian carcinomas among different races. Type II cancer was significantly more common in Europe and the 
USA than in Asia (p<0.001). Conversely, type I was relatively common in Asia. There were unidentified cancers in addition to type I and type II cancers. 
 
Furthermore, annual screening may improve 
prognoses, even in cases of type II ovarian carcinoma. 
The MMS method employed in the UKCTOCS can be 
used to detect cancer at an earlier stage than the PLCO 
method. It showed a significant reduction in mortality 
due to its extended screening and follow-up periods. 
Conclusion 
In summary, annual screening with the use of 
CA125/TVS can detect the precursors of type I 
ovarian carcinoma, such as cystic tumors, and identify 
patients who should be closely observed. Thus annual 
screening may be useful for detecting type I ovarian 
carcinoma at an earlier stage. Furthermore, annual 
screening may improve the prognoses or induce the 
down staging (from stage IV to stage III) of cases of 
type II ovarian carcinoma, which would further 
increase its efficacy in Asia, and also make it effective 
in Europe and the USA, just as the UKCTOCS showed 
a significant mortality reduction in the UK. 
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